4000-520-616
欢迎来到免疫在线！(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
产品库 品牌馆 现货促销 技术交流 新闻动态 联系我们
bdbiosciences
主营：主营：医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
咨询热线电话
4000-520-616
公司首页 公司介绍 产品中心 新闻动态 联系方式 在线下单
当前位置： 首页 > 产品中心 > peptide > BD Biosciences/CD45 FITC/Gly A PE/CD41a PerCP-Cy™5.5/333175
商品详细BD Biosciences/CD45 FITC/Gly A PE/CD41a PerCP-Cy™5.5/333175
BD Biosciences/CD45 FITC/Gly A PE/CD41a PerCP-Cy™5.5/333175
BD Biosciences/CD45 FITC/Gly A PE/CD41a PerCP-Cy™5.5/333175
商品编号： 333175
品牌： bdbiosciences
市场价： ¥0.00
美元价： 0.00
产地： 美国(厂家直采)
公司：
产品分类： 多肽合成
公司分类： peptide
联系Q Q： 3392242852
电话号码： 4000-520-616
电子邮箱： info@ebiomall.com
立即询价
商品介绍
Product DetailsRecommended AssayReferences

Description

BD Oncomark™ CD45 FITC/Anti–glycophorin A PE/CD41a PerCP-Cy5.5 is intended for in vitro flow cytometric immunophenotyping of the development in the erythroid, leucocytic, and megakaryocytic cell lineages in peripheral blood and bone marrow. Megakaryocytes co-express the platelet-specific glycoprotein gpIIb/IIIa (CD41a) and CD45 throughout their differentiation. In contrast, glycophorin A expression is present during erythroid cell development, with a gradual decrease in CD45 intensity during erythroid maturation. Using this approach, erythroid and lymphoid cells can be clearly distinguished based upon their antigenic expression. CD45/Anti–glycophorin A/CD41a assays are used in the diagnosis of hematologic disorders.

Contents

SpecificityCloneFormatIsotypeEntrez Gene ID
CD452D1FITCIgG1, κ
CD235a (Glycophorin A)GA-R2 (HIR2)PEIgG2b, κ
CD41aHIP8PerCP-Cy™5.5IgG1, κ3674
Resources & Tools
SpectrumViewerDownload MSDS
Preparation and Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

  1. Protection of Laboratory Workers from Occupationally Acquired Infections–Second Edition; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 2001. NCCLS document M29-A2.

  2. Bain B, Catovsky D. Current concerns in haematology 2: classification of acute leukaemia. J Clin Pathol. 1990;43:882-887.

  3. Bain BJ. Immunological markers in acute myeloid leukaemia. Leukaemia Diagnosis: A Guide to the FAB Classification. 1990:65-68.

  4. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.

  5. de Haas M, von dem Borne A. CD41/CD61 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AEGK, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. 1997:643-645.

  6. de Vries E, De Bruin-Versteeg S, Comans-Bitter WM, et al. Correction for erythroid cell contamination in microassay for immunophenotyping of neonatal lymphocytes. Arch Dis Child Fetal Neonatal Ed. 1999;80:226-229.

  7. Feng R, Shimazaki C, Inaba T, et al. CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21:1217-1222.

  8. Gahmberg CG, Jokinen M, Andersson LC. Expression of the major sialoglycoprotein (glycophorin) on erythroid cells in human bone marrow. Blood. 1978;52:379-387.

  9. Helleberg C, Knudsen H, Hansen PB, et al. CD34+ megakaryoblastic leukaemic cells are CD38-, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? Leukemia. 1997;11:830-834.

  10. Jackson A. Basic phenotyping of lymphocytes: selection and testing of reagents and interpretation of data. Clin Immunol Newslett. 1990;10:43-55.

  11. Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.

  12. Jennings LK, Ashmun RA, Wang WC, Dockter ME. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann"s thrombasthenia in whole blood by flow cytometry. Blood. 1986;68:173-179.

  13. Jokinen M, Ehnholm C, Väisänen-Rhen V, et al. Identification of the major human sialoglycoprotein from red cells, glycophorin AM, as the receptor for Escherichia coli IH 11165 and characterization of the receptor site. Eur J Biochem. 1985;147:47-52.

  14. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. I. Normal erythroid development. Blood. 1987;69:255-263.

  15. Qiao X, Loudovaris M, Unverzagt K, et al. Immunocytochemistry and flow cytometry evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells. Cytometry. 1996;23(3):250-259.

  16. Rogers CE, Bradley MS, Palsson BO, Koller MR. Flow cytometric analysis of human bone marrow perfusion cultures: erythroid development and relationship with burst-forming units-erythroid. Exp Hematol. 1996;24:597-604.

  17. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-895.

  18. Schwinzer R. Cluster report: CD45/CD45R. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press Inc; 1989:628-634.

  19. Stelzer GT, Marti G, Hurley A, McCoy P, Jr., Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30:214-230.

  20. Templeton TJ, Keister DB, Muratova O, Procter JL, Kaslow DC. Adherence of erythrocytes during exflagellation of plasmodium falciparum microgametes is dependent on erythrocyte surface sialic acid and glycophorins. J Exp Med. 1998;187:1599-1609.

  21. von dem Borne AEGKr, Modderman PW, Admiraal LG, Nieuwenhuis HK. Platelet antibodies, the overall results. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:951-977.

  22. Wise GE, Oakford LX, Dzandu JK. Ultrastructure of a transmembrane glycoprotein, glycophorin A. Tissue & Cell. 1988;20:219-227.

  23. Wybenga LE, Epand RF, Nir S, et al. Glycophorin as a receptor for sendai virus. Biochem. 1996;35:9513-9518.

品牌介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。公司的服务对象包括医疗机构，生命科学研究所，临床实验室，工业单位和普通大众。BD has state-of-the-art facilities around the globe that provide an environment that enables our highly talented workforce to be the best at their professions. We hire associates who have a passion and commitment to advancing the world of health. We are always seeking great people to join our company on its journey to greatness.BDRat Granulocytes Pure RP-1  500ug550002BDMs Ig Kpa Lgt Chain FITC 187.1  500ug550007BDICC Fixation Buffer 100mL550011BDMs CD210 NALE 1B1.3a 500ug550019BDMs CD51 Pure RMV-7 100ug550026BDMs CD5 APC 53-7.3 100ug550037BDHu CD62E PE-Cy5 68-5H11 100Tst550041BDHu CD95 Pure EOS9.1  100ug550052BDHam IgG2 Kpa ItCl FITC B81-3 250ug550057BDMs Crry/p65 Pure 1F2 100ug550059BDMs IL-4 Recom Protein 10ug550068BDMs IL-2 Recom Protein 20ug550070BDHu IL-6 Recom Protein 10ug550072BDHu MIP-1 Bta PE D21-1351 100ug550082BDMs IgG1 PE A85-1 100ug550084BDHam IgG2 Kpa ItCl PE B81-3 100ug550086BDHu CD142 Pure HTF-1 100ug550254BDHu CD1d PE CD1d42 100Tst550256BDHu CD73 PE AD2 100Tst550258BDHu CD103 FITC Ber-ACT8 100Tst550260BDMs CD11c APC HL3 100ug550268BDMs CD72b/c Aloatg PE JY/93 100ug550270BDRat CD32 Pure D34-485 500ug550272BDRat CD32 NALE D34-485 500ug550274BDMs CD3e IHC Pure 145-2C11 1mL550277BDMs CD4 IHC Pure H129.19 1mL550280BDMs CD8a IHC Pure 53-6.7 1mL
公司介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗，提高传染性疾病诊断的质量和速度，推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立，总部位于美国新泽西州的富兰克林湖，业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类，生产销售包
品牌分类
HIV Reagent Kits Stem Cell Enumeration BD Multicheck™ Control Other Species Cell Separation Reagents BD Facsunt™ 控制套件 Single-Color Antibodies BD™ Stem Cell Control Kit Sample Multiplexing Reagents 纯化抗体
显示分类
联络我们
服务热线：4000-520-616
（限工作日9:00-18:00）
QQ ：1570468124
手机：18915418616
快速导航：
总部地址：
江苏省苏州市工业园区星湖街218号 苏州生物医药产业园一期（生物纳米园）A4-216(邮编：215125)
工作时间：周一至周五9:00~18:00
技术支持：
短信：18915418616
服务热线：
4000-520-616（全国）
☏  0512-67156496（苏州）
版权信息：
©  2015-2022 苏州蚂蚁淘生物科技有限公司 版权所有 中国
网站备案：
友情链接：
免责声明：
本站有部分内容来自互联网，如无意中侵犯了某个媒体 、公司 、企业或个人等的知识产权，请来电或致函告之，
本网站将在规定时间内给予删除等相关处理。
扫描二维码关注官方微信
获取最新促销及产品信息